Arkolith/Insider Trading/BNTC/Form 4

Suvretta Capital Management, LLC

Director, 10% OwnerBenitec Biopharma Inc. (BNTC) · full profile →Form 4 · filed Apr 2, 2025
Net Buying
Open-Market Buys
$212K
Open-Market Sells
$0
Net Open-Market Flow
$212K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2025Buy(P)5K$13.22$67K8.8M
Mar 31, 2025Buy(P)670$13.22$9K1.1M
Mar 31, 2025Buy(P)10K$12.63$120K8.8M
Mar 31, 2025Buy(P)1K$12.63$16K1.1M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899140-25-000486) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML